Elevation Oncology, Inc. ELEV
0.37 0.00 (+0.00%)
At closeJul 23, 2025, 4:00 PM EDT
0.365 Day range 0.365
0.44 52-week range 5.83
- Market cap
- 33.90M
- EPS (ttm)
- -0.80
- Shares out
- 59.12M
- Forward P/E
- -0.63
- Volume
- 4.82M
- Avg volume
- 773.88K
- Open
- 0.365
- Previous close
- 0.365
- Day's range
- 0.365 – 0.365
- 52-week range
- 0.44 – 5.83
- Beta
- 1.25
- Analysts
- Strong Buy
- Price target
- 7.00 (+1817.8%)
- Earnings date
- Aug 6, 2024
2Y -0.7250 (-66.51%)
Key statistics
- Enterprise value
- -37.76M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.49
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -25.37M
- Total cash
- 103.07M
- Total debt
- 31.02M
- Return on equity
- -63.67%
- Short % of float
- 10.96%
- 50-day average
- 0.60106
- 200-day average
- 2.17
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 7.00 +1817.8% upside
Now 0.365
- Target (low)
- 5.00
- Target (mean)
- 7.00
- Target (high)
- 10.00
Ratings (0m) 7 7 buy · 0 hold · 0 sell
- Strong buy3
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 6, 2024
Expected Aug 6, 2024. Consensus EPS estimate -0.2075.
Financials — quick view
ELEV Revenue — quarterly 0
ELEV Net income — quarterly -14.21M
ELEV EPS — quarterly -0.24
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.20 | -0.22 | -0.02 | -10.00% |
| Aug 6, 2024 | Jun 1, 2024 | -0.23 | — | — | — |
| Aug 6, 2024 | Jun 1, 2024 | -0.23 | -0.18 | +0.05 | +21.74% |
| May 2, 2024 | Mar 1, 2024 | -0.21 | — | — | — |
| May 2, 2024 | Mar 1, 2024 | -0.21 | -0.23 | -0.02 | -9.52% |
| Mar 6, 2024 | Dec 1, 2023 | -0.21 | -0.19 | +0.02 | +9.52% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Dec 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 6, 2024 | Stephens & Co. | reit | Overweight | Overweight |
| Aug 7, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 15, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Jun 28, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
About Elevation Oncology, Inc.
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- elevationoncology.com
News
' Medicare Part D Drug Plan Premiums Set to Rise'- WSJ 
'Senate Republicans to Omit Medicare Advantage Cuts in Tax Bill'- Bloomberg 
HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Elevation Oncology, Inc. (NASDAQ: ELEV) 
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of Shareholders 
ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc. - ELEV 
This McDonald's Analyst Turns Bearish; Here Are Top 4 Downgrades For Tuesday 
ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders 
Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right 
'Medicare Surfaces as Target for Cuts to Pay for Trump Tax Bill'- Bloomberg 
'Medicare Surfaces as Target for Cuts to Pay for Trump Tax Bill' -Bloomberg
Your note
Sign in to keep a note on ELEV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CLACKSON TIMOTHY P | Director | Stock Gift | Aug 31, 2023 | 47,330 |
| FERRA JOSEPH J. JR. | Chief Executive Officer | Conversion of Exercise of derivative security | Dec 15, 2024 | 109,482 |
| FURLONG TAMMY CPA | Chief Financial Officer | Conversion of Exercise of derivative security | Nov 14, 2024 | 1,410 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 10.14% | 5,993,579 | 3.44M | Sep 29, 2024 |
| Tang Capital Management, LLC | 8.05% | 4,760,000 | 2.73M | Sep 29, 2024 |
| Goldman Sachs Group Inc | 6.75% | 3,988,472 | 2.29M | Sep 29, 2024 |
| Farallon Capital Management LLC | 5.97% | 3,527,482 | 2.02M | Sep 29, 2024 |
| Vanguard Group Inc | 5.20% | 3,071,580 | 1.76M | Sep 29, 2024 |
| BVF Inc. | 5.02% | 2,966,836 | 1.70M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.77% | 1,635,650 | 938.04K | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.23% | 1,316,466 | 754.99K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.03% | 608,571 | 349.01K | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.93% | 547,177 | 313.81K | Aug 30, 2024 |
| Vanguard U.S. Momentum Factor ETF | 0.73% | 431,953 | 247.72K | Aug 30, 2024 |
| Fidelity Extended Market Index Fund | 0.50% | 294,425 | 168.85K | Oct 30, 2024 |